Boston Life Sciences to begin clinical trials with Altropane.BOSTON--(BUSINESS WIRE)--Jan. 13, 1997--Boston Life Sciences Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BLSI BLSI Boston Life Sciences, Inc. ) announced that the company had filed its Investigational New Drug (IND) application for Altropane(TM), and would initiate its corporate Phase I/II clinical trial within the next few weeks. "Based on the exciting and encouraging results from our Physician's Sponsored Phase I/II study at the Mass. General Hospital last year, we have now planned an accelerated clinical development program. Our objective is to complete our Phase I/II and Phase III trials and, contingent upon prompt patient enrollment and satisfactory clinical results, to file for marketing approval before the end of 1997," stated Marc Lanser, M.D., Chief Scientific Officer of BLSI. Dr. Lanser further stated that the company had already begun preliminary discussions with several potential manufacturing, distribution, and marketing partners. BLSI is engaged in the research and development of novel treatments for cancer, autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . BLSI's products in clinical trials or in pre-clinical development include the above-mentioned Altropane; an anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; THERAFECTIN(R) for the treatment of Rheumatoid Arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. ; and two transcription factors to control the expression of molecules associated with autoimmune disease autoimmune disease, any of a number of abnormal conditions caused when the body produces antibodies to its own substances. In rheumatoid arthritis, a group of antibody molecules called collectively RF, or rheumatoid factor, is complexed to the individual's own gamma and allergies. CONTACT: BLSI, Boston Marc E. Lanser, M.D. 617/425-0200 or Martin E. Janis & Co. Inc., Chicago Bev Jedynak 312/943-1100 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion